{
  "as_of": "2026-11-03",
  "track": "anti-infective",
  "source_url": "https://drugnews.com.tw/en/asia-anti-infective-leaders.html",
  "headers": [
    "rank",
    "asset",
    "inn",
    "originator",
    "country",
    "target",
    "mechanism",
    "highest_stage",
    "indications",
    "trial_ids",
    "overseas_rights_holder",
    "deal_date",
    "upfront",
    "total_value",
    "latest_event",
    "latest_event_date",
    "source_urls",
    "source_date"
  ],
  "rows": [
    [
      "1",
      "Favipiravir (Avigan)",
      "favipiravir",
      "Toyama Chemical (now FUJIFILM Toyama Chemical)",
      "Japan",
      "Viral RNA polymerase",
      "RNA polymerase inhibitor",
      "Approved — Japan (2014-03; restricted influenza use)",
      "Novel/re-emerging influenza (restricted indication); SFTS (Japan approval 2024-06)",
      "jRCT2061240089",
      "Dr. Reddy's Laboratories / Global Response Aid (2020 overseas development/commercialisation alliance; current status not fully verified)",
      "2020-06 (agreement month; announced 2020-07-01)",
      "Not disclosed",
      "Not disclosed",
      "Company pipeline records Japan approval for SFTS in June 2024",
      "2024-06",
      "https://www.fujifilmpharma.com/news/announcement-on-the-start-of-patient-enrollment-for-phase-iii-clinical-study-in-japan-of-the-antiviral-drug-favipiravir-for-ixodid-tick-borne-infectious-disease-serious-fever-with-thrombocytopenia-sy/ | https://www.fujifilmpharma.com/pipeline/ | https://www.fujifilm.com/jp/ja/news/list/5109 | https://ir.fujifilm.com/en/investors/ir-materials/earnings-release/main/01/teaserItems1/00/linkList/04/link/ff_fr_20213q1_all.pdf | https://rctportal.mhlw.go.jp/en/detail?trial_id=jRCT2061240089",
      "2024-06"
    ],
    [
      "2",
      "Baloxavir marboxil (Xofluza; S-033188)",
      "baloxavir marboxil",
      "Shionogi & Co., Ltd.",
      "Japan",
      "Influenza cap-dependent endonuclease",
      "Cap-dependent endonuclease inhibitor",
      "Approved — Japan (2018-02)",
      "Treatment of influenza; post-exposure prophylaxis (jurisdiction-specific labels)",
      "NCT02954354 | NCT07827599",
      "Roche / Genentech (worldwide excluding Japan and Taiwan)",
      "2016-02-29",
      "Not disclosed",
      "Not disclosed",
      "New baloxavir post-exposure prophylaxis Phase 3 study registry updated; recruiting",
      "2026-10-22",
      "https://med.shionogi.co.jp/products/medicine/xofluza.html?channel=main | https://www.roche.com/investors/updates/inv-update-2021-01-11 | https://www.shionogi.com/global/en/company/outline.html | https://www.shionogi.com/global/en/news/2016/02/160229.html | https://clinicaltrials.gov/study/NCT02954354 | https://clinicaltrials.gov/study/NCT07827599",
      "2026-10-22"
    ],
    [
      "3",
      "Albuvirtide (Aikening; ABT)",
      "albuvirtide",
      "Frontier Biotechnologies Inc.",
      "China",
      "HIV-1 fusion",
      "Long-acting HIV-1 fusion inhibitor",
      "Approved — China (2018-05)",
      "HIV-1 infection with other antiretrovirals in treatment-experienced patients",
      "NCT02369965",
      "None reported",
      "—",
      "—",
      "—",
      "TALENT albuvirtide Phase 3 registry updated; completed",
      "2021-10-06",
      "https://en.frontierbiotech.com/detail/109.html | https://en.frontierbiotech.com/ | https://clinicaltrials.gov/study/NCT02369965",
      "2021-10-06"
    ],
    [
      "4",
      "Cefiderocol (Fetroja / Fetcroja; S-649266)",
      "cefiderocol",
      "Shionogi & Co., Ltd.",
      "Japan",
      "Bacterial cell-wall synthesis",
      "Siderophore cephalosporin antibacterial",
      "Approved — United States (2019-11)",
      "Complicated urinary tract infections; hospital/ventilator-associated bacterial pneumonia (jurisdiction-specific labels)",
      "NCT02714595",
      "GARDP / sublicensees (135-country access licence); Shionogi group retains other markets",
      "2022-06-15",
      "Not disclosed",
      "Not disclosed",
      "Shionogi announced China NMPA approval for complicated urinary tract infections",
      "2026-01-08",
      "https://www.shionogi.com/us/en/news/2019/11/fetroja-cefiderocol-approved-by-the-fda-for-treatment-of-complicated-urinary-tract-infections-cuti-in-adult-patients-with-limited-or-no-alternative-treatment-options.html | https://www.shionogi.com/global/en/news/2026/01/e20260108.html | https://www.shionogi.com/global/en/company/outline.html | https://www.shionogi.com/global/en/news/2022/06/e220615.html | https://clinicaltrials.gov/study/NCT02714595",
      "2026-01-08"
    ],
    [
      "5",
      "Azvudine",
      "azvudine",
      "Henan Genuine Biotech Co., Ltd.",
      "China",
      "HIV-1 reverse transcriptase / Vif",
      "Nucleoside reverse-transcriptase and Vif inhibitor (HIV indication)",
      "Approved — China (2021-07; conditional)",
      "HIV-1 infection (combination therapy); COVID-19 (China conditional approval 2022-07)",
      "NCT04303598",
      "None reported",
      "—",
      "—",
      "—",
      "Company history records April 2026 application to convert HIV conditional approval to regular approval",
      "2026-04",
      "https://www.nmpa.gov.cn/zhuanti/cxylqx/cxypxx/20210721142223181.html?m=&type=pc | https://en.genuine-bio.com/about.html | https://clinicaltrials.gov/study/NCT04303598",
      "2026-04"
    ],
    [
      "6",
      "Ensitrelvir (Xocova; S-217622)",
      "ensitrelvir",
      "Shionogi & Co., Ltd. / Hokkaido University",
      "Japan",
      "SARS-CoV-2 3CL protease",
      "3CL protease inhibitor",
      "Approved — Japan (2022-11; emergency; standard 2024-03)",
      "COVID-19 treatment (Japan); post-exposure prophylaxis (United States approval 2026)",
      "NCT05897541",
      "Medicines Patent Pool (117-country voluntary licence); Juniper Therapeutics / Therapeutix (Singapore; via Shionogi Hong Kong, formerly Ping An-Shionogi)",
      "2022-10-04 (MPP); 2023-12-06 (Juniper normal-approval/sales rights; disclosed 2023-12-19)",
      "Not disclosed",
      "Not disclosed",
      "SCORPIO-PEP Phase 3 registry updated; completed, after US post-exposure prophylaxis approval",
      "2026-10-07",
      "https://www.shionogi.com/global/en/news/2022/11/e20221122.html | https://www.shionogi.com/us/en/news/2024/03/shionogi-announces-xocova-ensitrelvir-fumaric-acid-obtained-standard-approval-in-japan-for-the-treatment-of-sars-cov-2-infection.html | https://www.shionogi.com/global/en/news/2026/06/20260601.html | https://www.shionogi.com/global/en/company/outline.html | https://www.shionogi.com/global/en/news/2022/10/20221004.html | https://www.shionogi.com/global/en/news/2023/12/e20231219.html | https://www.shionogi.com/content/dam/shionogi/global/investors/ir-library/annual-securities-report/Annual%20Securities%20Report%20160th.pdf | https://clinicaltrials.gov/study/NCT05897541",
      "2026-10-07"
    ],
    [
      "7",
      "Simnotrelvir / ritonavir (Xiannuoxin; SIM0417)",
      "simnotrelvir / ritonavir",
      "Simcere Pharmaceutical / Shanghai Institute of Materia Medica / Wuhan Institute of Virology",
      "China",
      "SARS-CoV-2 3CL protease",
      "3CL protease inhibitor co-packaged with ritonavir",
      "Approved — China (2023-01; conditional; regular 2024-07)",
      "Mild to moderate COVID-19 in adults",
      "NCT05506176",
      "None reported",
      "—",
      "—",
      "—",
      "Company announced conversion to regular China approval (announcement refers to July 11, 2024)",
      "2024-07-23",
      "https://www.simcere.com/en/news/detail.aspx?mtt=464 | https://www.simcere.com/UploadFile/20231030101349.pdf | https://clinicaltrials.gov/study/NCT05506176",
      "2024-07-23"
    ],
    [
      "8",
      "Leritrelvir (RAY1216; Leruiling)",
      "leritrelvir",
      "Guangdong Raynovent Biotech",
      "China",
      "SARS-CoV-2 3CL protease",
      "Oral 3CL protease inhibitor",
      "Approved — China (2023-03; conditional)",
      "Mild to moderate COVID-19 in adults",
      "NCT05620160",
      "None reported",
      "—",
      "—",
      "—",
      "Company year-end review records December 2023 national reimbursement-list inclusion",
      "2023-12-13",
      "https://www.raynovent.com/ray/news/60.html | https://www.raynovent.com/ray/news/34.html | https://www.raynovent.com/ray/contact.html | https://clinicaltrials.gov/study/NCT05620160",
      "2024-01-03"
    ]
  ],
  "row_sources": [
    [
      {
        "url": "https://www.fujifilmpharma.com/news/announcement-on-the-start-of-patient-enrollment-for-phase-iii-clinical-study-in-japan-of-the-antiviral-drug-favipiravir-for-ixodid-tick-borne-infectious-disease-serious-fever-with-thrombocytopenia-sy/",
        "source_date": "2024-06"
      },
      {
        "url": "https://www.fujifilmpharma.com/pipeline/",
        "source_date": "2024-06"
      },
      {
        "url": "https://www.fujifilm.com/jp/ja/news/list/5109",
        "source_date": "2024-06"
      },
      {
        "url": "https://ir.fujifilm.com/en/investors/ir-materials/earnings-release/main/01/teaserItems1/00/linkList/04/link/ff_fr_20213q1_all.pdf",
        "source_date": "2024-06"
      },
      {
        "url": "https://rctportal.mhlw.go.jp/en/detail?trial_id=jRCT2061240089",
        "source_date": "2024-06"
      }
    ],
    [
      {
        "url": "https://med.shionogi.co.jp/products/medicine/xofluza.html?channel=main",
        "source_date": "2026-10-22"
      },
      {
        "url": "https://www.roche.com/investors/updates/inv-update-2021-01-11",
        "source_date": "2026-10-22"
      },
      {
        "url": "https://www.shionogi.com/global/en/company/outline.html",
        "source_date": "2026-10-22"
      },
      {
        "url": "https://www.shionogi.com/global/en/news/2016/02/160229.html",
        "source_date": "2026-10-22"
      },
      {
        "url": "https://clinicaltrials.gov/study/NCT02954354",
        "source_date": "2026-10-22"
      },
      {
        "url": "https://clinicaltrials.gov/study/NCT07827599",
        "source_date": "2026-10-22"
      }
    ],
    [
      {
        "url": "https://en.frontierbiotech.com/detail/109.html",
        "source_date": "2021-10-06"
      },
      {
        "url": "https://en.frontierbiotech.com/",
        "source_date": "2021-10-06"
      },
      {
        "url": "https://clinicaltrials.gov/study/NCT02369965",
        "source_date": "2021-10-06"
      }
    ],
    [
      {
        "url": "https://www.shionogi.com/us/en/news/2019/11/fetroja-cefiderocol-approved-by-the-fda-for-treatment-of-complicated-urinary-tract-infections-cuti-in-adult-patients-with-limited-or-no-alternative-treatment-options.html",
        "source_date": "2026-01-08"
      },
      {
        "url": "https://www.shionogi.com/global/en/news/2026/01/e20260108.html",
        "source_date": "2026-01-08"
      },
      {
        "url": "https://www.shionogi.com/global/en/company/outline.html",
        "source_date": "2026-01-08"
      },
      {
        "url": "https://www.shionogi.com/global/en/news/2022/06/e220615.html",
        "source_date": "2026-01-08"
      },
      {
        "url": "https://clinicaltrials.gov/study/NCT02714595",
        "source_date": "2026-01-08"
      }
    ],
    [
      {
        "url": "https://www.nmpa.gov.cn/zhuanti/cxylqx/cxypxx/20210721142223181.html?m=&type=pc",
        "source_date": "2026-04"
      },
      {
        "url": "https://en.genuine-bio.com/about.html",
        "source_date": "2026-04"
      },
      {
        "url": "https://clinicaltrials.gov/study/NCT04303598",
        "source_date": "2026-04"
      }
    ],
    [
      {
        "url": "https://www.shionogi.com/global/en/news/2022/11/e20221122.html",
        "source_date": "2026-10-07"
      },
      {
        "url": "https://www.shionogi.com/us/en/news/2024/03/shionogi-announces-xocova-ensitrelvir-fumaric-acid-obtained-standard-approval-in-japan-for-the-treatment-of-sars-cov-2-infection.html",
        "source_date": "2026-10-07"
      },
      {
        "url": "https://www.shionogi.com/global/en/news/2026/06/20260601.html",
        "source_date": "2026-10-07"
      },
      {
        "url": "https://www.shionogi.com/global/en/company/outline.html",
        "source_date": "2026-10-07"
      },
      {
        "url": "https://www.shionogi.com/global/en/news/2022/10/20221004.html",
        "source_date": "2026-10-07"
      },
      {
        "url": "https://www.shionogi.com/global/en/news/2023/12/e20231219.html",
        "source_date": "2026-10-07"
      },
      {
        "url": "https://www.shionogi.com/content/dam/shionogi/global/investors/ir-library/annual-securities-report/Annual%20Securities%20Report%20160th.pdf",
        "source_date": "2026-10-07"
      },
      {
        "url": "https://clinicaltrials.gov/study/NCT05897541",
        "source_date": "2026-10-07"
      }
    ],
    [
      {
        "url": "https://www.simcere.com/en/news/detail.aspx?mtt=464",
        "source_date": "2024-07-23"
      },
      {
        "url": "https://www.simcere.com/UploadFile/20231030101349.pdf",
        "source_date": "2024-07-23"
      },
      {
        "url": "https://clinicaltrials.gov/study/NCT05506176",
        "source_date": "2024-07-23"
      }
    ],
    [
      {
        "url": "https://www.raynovent.com/ray/news/60.html",
        "source_date": "2024-01-03"
      },
      {
        "url": "https://www.raynovent.com/ray/news/34.html",
        "source_date": "2024-01-03"
      },
      {
        "url": "https://www.raynovent.com/ray/contact.html",
        "source_date": "2024-01-03"
      },
      {
        "url": "https://clinicaltrials.gov/study/NCT05620160",
        "source_date": "2024-01-03"
      }
    ]
  ],
  "records": [
    {
      "rank": "1",
      "asset": "Favipiravir (Avigan)",
      "inn": "favipiravir",
      "originator": "Toyama Chemical (now FUJIFILM Toyama Chemical)",
      "country": "Japan",
      "target": "Viral RNA polymerase",
      "mechanism": "RNA polymerase inhibitor",
      "highest_stage": "Approved — Japan (2014-03; restricted influenza use)",
      "indications": "Novel/re-emerging influenza (restricted indication); SFTS (Japan approval 2024-06)",
      "trial_ids": "jRCT2061240089",
      "overseas_rights_holder": "Dr. Reddy's Laboratories / Global Response Aid (2020 overseas development/commercialisation alliance; current status not fully verified)",
      "deal_date": "2020-06 (agreement month; announced 2020-07-01)",
      "upfront": "Not disclosed",
      "total_value": "Not disclosed",
      "latest_event": "Company pipeline records Japan approval for SFTS in June 2024",
      "latest_event_date": "2024-06",
      "source_urls": "https://www.fujifilmpharma.com/news/announcement-on-the-start-of-patient-enrollment-for-phase-iii-clinical-study-in-japan-of-the-antiviral-drug-favipiravir-for-ixodid-tick-borne-infectious-disease-serious-fever-with-thrombocytopenia-sy/ | https://www.fujifilmpharma.com/pipeline/ | https://www.fujifilm.com/jp/ja/news/list/5109 | https://ir.fujifilm.com/en/investors/ir-materials/earnings-release/main/01/teaserItems1/00/linkList/04/link/ff_fr_20213q1_all.pdf | https://rctportal.mhlw.go.jp/en/detail?trial_id=jRCT2061240089",
      "source_date": "2024-06"
    },
    {
      "rank": "2",
      "asset": "Baloxavir marboxil (Xofluza; S-033188)",
      "inn": "baloxavir marboxil",
      "originator": "Shionogi & Co., Ltd.",
      "country": "Japan",
      "target": "Influenza cap-dependent endonuclease",
      "mechanism": "Cap-dependent endonuclease inhibitor",
      "highest_stage": "Approved — Japan (2018-02)",
      "indications": "Treatment of influenza; post-exposure prophylaxis (jurisdiction-specific labels)",
      "trial_ids": "NCT02954354 | NCT07827599",
      "overseas_rights_holder": "Roche / Genentech (worldwide excluding Japan and Taiwan)",
      "deal_date": "2016-02-29",
      "upfront": "Not disclosed",
      "total_value": "Not disclosed",
      "latest_event": "New baloxavir post-exposure prophylaxis Phase 3 study registry updated; recruiting",
      "latest_event_date": "2026-10-22",
      "source_urls": "https://med.shionogi.co.jp/products/medicine/xofluza.html?channel=main | https://www.roche.com/investors/updates/inv-update-2021-01-11 | https://www.shionogi.com/global/en/company/outline.html | https://www.shionogi.com/global/en/news/2016/02/160229.html | https://clinicaltrials.gov/study/NCT02954354 | https://clinicaltrials.gov/study/NCT07827599",
      "source_date": "2026-10-22"
    },
    {
      "rank": "3",
      "asset": "Albuvirtide (Aikening; ABT)",
      "inn": "albuvirtide",
      "originator": "Frontier Biotechnologies Inc.",
      "country": "China",
      "target": "HIV-1 fusion",
      "mechanism": "Long-acting HIV-1 fusion inhibitor",
      "highest_stage": "Approved — China (2018-05)",
      "indications": "HIV-1 infection with other antiretrovirals in treatment-experienced patients",
      "trial_ids": "NCT02369965",
      "overseas_rights_holder": "None reported",
      "deal_date": "—",
      "upfront": "—",
      "total_value": "—",
      "latest_event": "TALENT albuvirtide Phase 3 registry updated; completed",
      "latest_event_date": "2021-10-06",
      "source_urls": "https://en.frontierbiotech.com/detail/109.html | https://en.frontierbiotech.com/ | https://clinicaltrials.gov/study/NCT02369965",
      "source_date": "2021-10-06"
    },
    {
      "rank": "4",
      "asset": "Cefiderocol (Fetroja / Fetcroja; S-649266)",
      "inn": "cefiderocol",
      "originator": "Shionogi & Co., Ltd.",
      "country": "Japan",
      "target": "Bacterial cell-wall synthesis",
      "mechanism": "Siderophore cephalosporin antibacterial",
      "highest_stage": "Approved — United States (2019-11)",
      "indications": "Complicated urinary tract infections; hospital/ventilator-associated bacterial pneumonia (jurisdiction-specific labels)",
      "trial_ids": "NCT02714595",
      "overseas_rights_holder": "GARDP / sublicensees (135-country access licence); Shionogi group retains other markets",
      "deal_date": "2022-06-15",
      "upfront": "Not disclosed",
      "total_value": "Not disclosed",
      "latest_event": "Shionogi announced China NMPA approval for complicated urinary tract infections",
      "latest_event_date": "2026-01-08",
      "source_urls": "https://www.shionogi.com/us/en/news/2019/11/fetroja-cefiderocol-approved-by-the-fda-for-treatment-of-complicated-urinary-tract-infections-cuti-in-adult-patients-with-limited-or-no-alternative-treatment-options.html | https://www.shionogi.com/global/en/news/2026/01/e20260108.html | https://www.shionogi.com/global/en/company/outline.html | https://www.shionogi.com/global/en/news/2022/06/e220615.html | https://clinicaltrials.gov/study/NCT02714595",
      "source_date": "2026-01-08"
    },
    {
      "rank": "5",
      "asset": "Azvudine",
      "inn": "azvudine",
      "originator": "Henan Genuine Biotech Co., Ltd.",
      "country": "China",
      "target": "HIV-1 reverse transcriptase / Vif",
      "mechanism": "Nucleoside reverse-transcriptase and Vif inhibitor (HIV indication)",
      "highest_stage": "Approved — China (2021-07; conditional)",
      "indications": "HIV-1 infection (combination therapy); COVID-19 (China conditional approval 2022-07)",
      "trial_ids": "NCT04303598",
      "overseas_rights_holder": "None reported",
      "deal_date": "—",
      "upfront": "—",
      "total_value": "—",
      "latest_event": "Company history records April 2026 application to convert HIV conditional approval to regular approval",
      "latest_event_date": "2026-04",
      "source_urls": "https://www.nmpa.gov.cn/zhuanti/cxylqx/cxypxx/20210721142223181.html?m=&type=pc | https://en.genuine-bio.com/about.html | https://clinicaltrials.gov/study/NCT04303598",
      "source_date": "2026-04"
    },
    {
      "rank": "6",
      "asset": "Ensitrelvir (Xocova; S-217622)",
      "inn": "ensitrelvir",
      "originator": "Shionogi & Co., Ltd. / Hokkaido University",
      "country": "Japan",
      "target": "SARS-CoV-2 3CL protease",
      "mechanism": "3CL protease inhibitor",
      "highest_stage": "Approved — Japan (2022-11; emergency; standard 2024-03)",
      "indications": "COVID-19 treatment (Japan); post-exposure prophylaxis (United States approval 2026)",
      "trial_ids": "NCT05897541",
      "overseas_rights_holder": "Medicines Patent Pool (117-country voluntary licence); Juniper Therapeutics / Therapeutix (Singapore; via Shionogi Hong Kong, formerly Ping An-Shionogi)",
      "deal_date": "2022-10-04 (MPP); 2023-12-06 (Juniper normal-approval/sales rights; disclosed 2023-12-19)",
      "upfront": "Not disclosed",
      "total_value": "Not disclosed",
      "latest_event": "SCORPIO-PEP Phase 3 registry updated; completed, after US post-exposure prophylaxis approval",
      "latest_event_date": "2026-10-07",
      "source_urls": "https://www.shionogi.com/global/en/news/2022/11/e20221122.html | https://www.shionogi.com/us/en/news/2024/03/shionogi-announces-xocova-ensitrelvir-fumaric-acid-obtained-standard-approval-in-japan-for-the-treatment-of-sars-cov-2-infection.html | https://www.shionogi.com/global/en/news/2026/06/20260601.html | https://www.shionogi.com/global/en/company/outline.html | https://www.shionogi.com/global/en/news/2022/10/20221004.html | https://www.shionogi.com/global/en/news/2023/12/e20231219.html | https://www.shionogi.com/content/dam/shionogi/global/investors/ir-library/annual-securities-report/Annual%20Securities%20Report%20160th.pdf | https://clinicaltrials.gov/study/NCT05897541",
      "source_date": "2026-10-07"
    },
    {
      "rank": "7",
      "asset": "Simnotrelvir / ritonavir (Xiannuoxin; SIM0417)",
      "inn": "simnotrelvir / ritonavir",
      "originator": "Simcere Pharmaceutical / Shanghai Institute of Materia Medica / Wuhan Institute of Virology",
      "country": "China",
      "target": "SARS-CoV-2 3CL protease",
      "mechanism": "3CL protease inhibitor co-packaged with ritonavir",
      "highest_stage": "Approved — China (2023-01; conditional; regular 2024-07)",
      "indications": "Mild to moderate COVID-19 in adults",
      "trial_ids": "NCT05506176",
      "overseas_rights_holder": "None reported",
      "deal_date": "—",
      "upfront": "—",
      "total_value": "—",
      "latest_event": "Company announced conversion to regular China approval (announcement refers to July 11, 2024)",
      "latest_event_date": "2024-07-23",
      "source_urls": "https://www.simcere.com/en/news/detail.aspx?mtt=464 | https://www.simcere.com/UploadFile/20231030101349.pdf | https://clinicaltrials.gov/study/NCT05506176",
      "source_date": "2024-07-23"
    },
    {
      "rank": "8",
      "asset": "Leritrelvir (RAY1216; Leruiling)",
      "inn": "leritrelvir",
      "originator": "Guangdong Raynovent Biotech",
      "country": "China",
      "target": "SARS-CoV-2 3CL protease",
      "mechanism": "Oral 3CL protease inhibitor",
      "highest_stage": "Approved — China (2023-03; conditional)",
      "indications": "Mild to moderate COVID-19 in adults",
      "trial_ids": "NCT05620160",
      "overseas_rights_holder": "None reported",
      "deal_date": "—",
      "upfront": "—",
      "total_value": "—",
      "latest_event": "Company year-end review records December 2023 national reimbursement-list inclusion",
      "latest_event_date": "2023-12-13",
      "source_urls": "https://www.raynovent.com/ray/news/60.html | https://www.raynovent.com/ray/news/34.html | https://www.raynovent.com/ray/contact.html | https://clinicaltrials.gov/study/NCT05620160",
      "source_date": "2024-01-03"
    }
  ]
}